Shinji Ohno

23.3k total citations · 2 hit papers
370 papers, 11.1k citations indexed

About

Shinji Ohno is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shinji Ohno has authored 370 papers receiving a total of 11.1k indexed citations (citations by other indexed papers that have themselves been cited), including 197 papers in Oncology, 126 papers in Cancer Research and 98 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shinji Ohno's work include Breast Cancer Treatment Studies (100 papers), HER2/EGFR in Cancer Research (85 papers) and Cancer Treatment and Pharmacology (67 papers). Shinji Ohno is often cited by papers focused on Breast Cancer Treatment Studies (100 papers), HER2/EGFR in Cancer Research (85 papers) and Cancer Treatment and Pharmacology (67 papers). Shinji Ohno collaborates with scholars based in Japan, United States and Germany. Shinji Ohno's co-authors include Fátima Cardoso, Philip Poortmans, Elżbieta Senkus, Frédérique Penault‐Llorca, S. Kyriakides, Sophia Zackrisson, Yusuke Yanagi, Keizō Sugimachi, Makoto Takeda and Isabel T. Rubio and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Shinji Ohno

361 papers receiving 10.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2019 1.4k citations Shinji Ohno et al. profile →
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2015 1.2k citations Shinji Ohno et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shinji Ohno Japan	51	4.5k	3.3k	2.4k	2.3k	1.6k	370	11.1k
D. Wallwiener Germany	54	5.0k 1.1×	3.4k 1.0×	2.5k 1.0×	1.7k 0.7×	1.9k 1.2×	608	12.8k
Justin Stebbing United Kingdom	67	6.1k 1.4×	3.5k 1.1×	4.3k 1.8×	2.1k 0.9×	1.7k 1.0×	524	14.8k
Gunnar B. Kristensen Norway	59	4.3k 0.9×	2.2k 0.7×	3.6k 1.5×	1.7k 0.7×	3.8k 2.4×	266	14.7k
Anthony F. Shields United States	59	4.5k 1.0×	2.0k 0.6×	2.2k 0.9×	2.9k 1.2×	1.5k 0.9×	360	11.9k
Kenneth K. Tanabe United States	58	4.4k 1.0×	1.7k 0.5×	3.2k 1.3×	2.0k 0.9×	1.9k 1.2×	236	11.6k
Pierce K. H. Chow Singapore	65	3.9k 0.9×	2.1k 0.6×	3.3k 1.3×	2.7k 1.2×	3.8k 2.4×	384	14.4k
Ruud H. Brakenhoff Netherlands	59	6.0k 1.3×	3.8k 1.1×	6.2k 2.5×	2.4k 1.0×	2.9k 1.8×	242	15.7k
Rosemarie Mick United States	72	6.2k 1.4×	2.1k 0.6×	3.5k 1.4×	2.6k 1.1×	2.0k 1.2×	265	14.4k
Roman Rouzier France	61	5.6k 1.2×	6.0k 1.8×	2.5k 1.0×	1.6k 0.7×	3.7k 2.3×	484	16.8k
Carolyn D. Runowicz United States	42	5.8k 1.3×	2.2k 0.7×	2.5k 1.0×	1.8k 0.8×	1.7k 1.1×	171	12.8k

Countries citing papers authored by Shinji Ohno

Since Specialization

Citations

This map shows the geographic impact of Shinji Ohno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shinji Ohno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shinji Ohno more than expected).

Fields of papers citing papers by Shinji Ohno

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shinji Ohno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shinji Ohno. The network helps show where Shinji Ohno may publish in the future.

Co-authorship network of co-authors of Shinji Ohno

This figure shows the co-authorship network connecting the top 25 collaborators of Shinji Ohno. A scholar is included among the top collaborators of Shinji Ohno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shinji Ohno. Shinji Ohno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Takahashi, Yōko, Tomo Osako, Takayuki Kobayashi, et al.. (2024). Serial single-cell RNA sequencing unveils drug resistance and metastatic traits in stage IV breast cancer. npj Precision Oncology. 8(1). 222–222. 3 indexed citations

Hara, Fumikata, et al.. (2024). Survey on adverse events associated with drug therapy for breast cancer patients. BMC Women s Health. 24(1). 545–545. 1 indexed citations

Inoue, Hiroaki, Rie Horii, Futoshi Akiyama, et al.. (2023). Intratumoral heterogeneity, treatment response, and survival outcome of ER‐positive HER2‐positive breast cancer. Cancer Medicine. 12(9). 10526–10535. 7 indexed citations

Kitano, Atsuko, Naomi Sakurai, Yuko Tanabe, et al.. (2023). Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives. Breast Cancer. 30(5). 820–830. 4 indexed citations

Sugishita, Yodo, Manabu Futamura, Tatsuro Furui, et al.. (2023). Oncofertility‐related psycho‐educational therapy for young adult patients with breast cancer and their partners: Randomized controlled trial. Cancer. 129(16). 2568–2580. 8 indexed citations

Yokokawa, Takashi, Kenichi Suzuki, Daiki Tsuji, et al.. (2023). Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study. Cancer Medicine. 12(18). 18745–18754. 2 indexed citations

Ithimakin, Suthinee, Napa Parinyanitikul, Sung‐Bae Kim, et al.. (2022). Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories. Journal of Breast Cancer. 25(3). 207–207. 5 indexed citations

Matsui, Takahiro, Masafumi Mimura, Seiji Taniguchi, et al.. (2022). Label‐free multiphoton excitation imaging as a promising diagnostic tool for breast cancer. Cancer Science. 113(8). 2916–2925. 6 indexed citations

Kubota, Marie, et al.. (2020). Lysosome-Associated Membrane Proteins Support the Furin-Mediated Processing of the Mumps Virus Fusion Protein. Journal of Virology. 94(12). 12 indexed citations

10.

Masuda, Takaaki, Hiroki Ueo, Yuichiro Kai, et al.. (2020). N-Cadherin mRNA Levels in Peripheral Blood Could Be a Potential Indicator of New Metastases in Breast Cancer: A Pilot Study. International Journal of Molecular Sciences. 21(2). 511–511. 9 indexed citations

11.

Yamashita, Toshinari, Hidetoshi Kawaguchi, Norikazu Masuda, et al.. (2020). Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study). Investigational New Drugs. 39(1). 217–225. 8 indexed citations

12.

Sato, Nobuaki, Norikazu Masuda, Takashi Morimoto, et al.. (2019). Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study. Cancer Medicine. 8(12). 5468–5481. 5 indexed citations

13.

Sato, Nobuaki, Norikazu Masuda, Takashi Morimoto, et al.. (2018). Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study. Cancer Medicine. 7(7). 3044–3056. 13 indexed citations

14.

Watanabe, Toru, Masaru Kuranami, Kenichi Inoue, et al.. (2017). Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. Cancer. 123(5). 759–768. 28 indexed citations

15.

Ohno, Shinji, Akemi Kataoka, Eriko Tokunaga, et al.. (2014). Unmet Information Needs and Quality of Life in Young Breast Cancer Survivors in Japan. Cancer Nursing. 38(6). E1–E11. 56 indexed citations

16.

Kosaka, Yoshimasa, Akemi Kataoka, Hiroshi Yamaguchi, et al.. (2012). Vascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancer. Breast Cancer Research. 14(5). R140–R140. 7 indexed citations

17.

Ohno, Shinji, et al.. (2011). Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?. Breast Cancer. 19(3). 212–217. 3 indexed citations

18.

Tsutsui, Shinichi, Shinji Ohno, Shigeru Murakami, et al.. (2002). EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. European Journal of Surgical Oncology. 28(4). 383–387. 34 indexed citations

19.

Ichiyoshi, Yuji, Shinichi Tomisaki, Shinya Oda, et al.. (1996). Macroscopic appearance and biological character of gastric cancer invading the muscularis propria.. PubMed. 43(9). 553–9. 7 indexed citations

20.

Ohno, Shinji, F. R. Strebel, L. Clifton Stephens, et al.. (1992). Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats.. PubMed. 52(15). 4096–101. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact